Denali Therapeutics 주식 가격. DNLI - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

23.31

매수가

19.32

매도가

24.50

거래량

1,013,494

22.72 일간 변동폭 23.69

14.56 52주 범위 33.33

market_cap

3.355B

전일 종가

23.04

개장가

23.04

최근 거래 시간

14642

23.31

(formt)

마지막 거래 시간

재정 규모

US$ 23,552,035

VWAP

23.2385

평균 볼륨(3m)

949,016

발행 주식

143,921,624

배당수익률

주가수익률

-23.10

주당순이익(EPS)

-1.01

매출

330.53M

순이익

-145.22M

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates ... Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. 더 보기

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.denalitherapeutics.com

본부

Wilmington, Delaware, USA

설립됨

Denali Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker DNLI. The last closing price for Denali Therapeutics was US$23.04. Over the last year, Denali Therapeutics shares have traded in a share price range of US$ 14.56 to US$ 33.33.

Denali Therapeutics currently has 143,921,624 shares in issue. The market capitalisation of Denali Therapeutics is US$3.32 billion. Denali Therapeutics has a price to earnings ratio (PE ratio) of -23.10.

Form 8-K - Current report

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in early 2025Preparing for commercial...

Form 4 - Statement of changes in beneficial ownership of securities

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...

Form 144 - Report of proposed sale of securities

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	3.67	18.6863543788	19.64	23.33	19.45	1214838	21.93780943	CS
4	2.6	12.5543215838	20.71	23.33	18.52	1019244	20.77904751	CS
12	-3.91	-14.3644379133	27.22	33.33	18.52	949016	23.69017067	CS
26	1.69	7.81683626272	21.62	33.33	18.52	920883	25.02882112	CS
52	6.02	34.8178137652	17.29	33.33	14.56	1045801	21.94479695	CS
156	-8.71	-27.2017489069	32.02	39.43	14.56	831326	24.7239704	CS
260	1.13	5.09467989179	22.18	93.94	12.39	740538	31.99265275	CS

DNLI - Frequently Asked Questions (FAQ)

What is the current Denali Therapeutics share price?

The current share price of Denali Therapeutics is US$ 23.31

How many Denali Therapeutics shares are in issue?

Denali Therapeutics has 143,921,624 shares in issue

What is the market cap of Denali Therapeutics?

The market capitalisation of Denali Therapeutics is USD 3.32B

What is the 1 year trading range for Denali Therapeutics share price?

Denali Therapeutics has traded in the range of US$ 14.56 to US$ 33.33 during the past year

What is the PE ratio of Denali Therapeutics?

The price to earnings ratio of Denali Therapeutics is -23.1

What is the cash to sales ratio of Denali Therapeutics?

The cash to sales ratio of Denali Therapeutics is 10.15

What is the reporting currency for Denali Therapeutics?

Denali Therapeutics reports financial results in USD

What is the latest annual turnover for Denali Therapeutics?

The latest annual turnover of Denali Therapeutics is USD 330.53M

What is the latest annual profit for Denali Therapeutics?

The latest annual profit of Denali Therapeutics is USD -145.22M

What is the registered address of Denali Therapeutics?

The registered address for Denali Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Denali Therapeutics website address?

The website address for Denali Therapeutics is www.denalitherapeutics.com

Which industry sector does Denali Therapeutics operate in?

Denali Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
BLBXBlackBoxStocks Inc	US$ 5.53 (227.22%)	229.07M
ASSTAsset Entities Inc	US$ 1.36 (51.11%)	121.67M
STAIScanTech AI Systems Inc	US$ 2.12 (44.22%)	51.68M
JYDJayud Global Logistics Ltd	US$ 3.53 (42.91%)	1.27M
NTRBNutriband Inc	US$ 7.39 (41.84%)	3.88M
STFSStar Fashion Culture Holdings Ltd	US$ 2.62 (-80.61%)	30.25M
HEPAHepion Pharmaceuticals Inc	US$ 0.135 (-58.05%)	39.89M
STBXStarBox Group Holdings Ltd	US$ 0.6201 (-36.50%)	1.63M
WHLRLWheeler Real Estate Investment Trust Inc	US$ 93.51 (-35.73%)	1
JUNSJupiter Neurosciences Inc	US$ 3.61 (-33.39%)	6.87M
IPAImmunoPrecise Antibodies Ltd	US$ 0.6446 (30.75%)	296.43M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.3191 (33.57%)	229.11M
BLBXBlackBoxStocks Inc	US$ 5.53 (227.22%)	229.08M
NVDANVIDIA Corporation	US$ 147.07 (4.43%)	216.62M
RGTIRigetti Computing Inc	US$ 13.89 (-0.64%)	154.54M